Skip to content
Markets

Kodiak Sciences Shares Soar 178% on Phase 3 Wins in Wet Macular Degeneration

Kodiak Sciences shares nearly tripled after Zenkuda and KSI-501 both met their main goals against aflibercept in the Phase 3 DAYBREAK trial in wet AMD. A US filing is planned for the fourth quarter.

A Kodiak Sciences building in Palo Alto, from the company's own photo shoot: glass and blue panels with a curved wave-shaped roof, behind a reflecting pool and paved courtyard.
Photo: Kodiak Sciences

Shares in Kodiak Sciences nearly tripled on Monday after the US biotech said both of its experimental eye drugs, Zenkuda and tabirafusp-ted (KSI-501), met their main goals in a late-stage trial in wet age-related macular degeneration.

Nearly tripled in one session

Kodiak, listed on Nasdaq under KOD, released topline results from its Phase 3 DAYBREAK study before the US open and held a webcast at 8:30 a.m. New York time. The shares were up 31.9% in pre-market trading, Finviz reported, and kept climbing through the session. The Motley Fool put the day's rise at about 178%.

Before the data, UBS reiterated a buy rating and an $80 price target on the stock, and said it expected Zenkuda to show noninferiority with dosing about every three to three and a half months. The stock's 52-week high before the news was $47.84.

DAYBREAK in three numbers

  • 178% approximate one-day rise in Kodiak shares
  • 54% of Zenkuda patients on six-monthly dosing after one year
  • 0% rate of eye inflammation with Zenkuda in the trial
The Nasdaq tower in New York's Times Square showing Kodiak Sciences Inc., October 5, 2018, KOD Nasdaq Listed on its screen, on the company's listing day.
The Nasdaq tower in New York's Times Square showing Kodiak Sciences Inc., October 5, 2018, KOD Nasdaq Listed on its screen, on the company's listing day. Photo: Kodiak Sciences

What DAYBREAK showed

DAYBREAK tested both drugs against aflibercept, the standard injected treatment sold as Eylea, in patients with wet AMD who had not been treated before. Wet AMD is caused by abnormal blood vessels under the retina that leak fluid and can quickly damage central vision.

The main measure was the change in best-corrected visual acuity from the start of the trial to the average of weeks 40, 44 and 48. Both drugs were noninferior to aflibercept, meaning they did at least about as well.

Zenkuda (tarcocimab tedromer)Tabirafusp-ted (KSI-501)Aflibercept
Dosing after loadingAs needed, every 4 to 24 weeksEvery 8 weeks, plus extra doses if neededPer label
Primary goalMet (P = .0007)Met (P = .0036)Comparator
Eye inflammation0%0.4%Not reported
Cataract events0.5%0%0.9%

Both drugs started with four monthly loading doses. Kodiak said Zenkuda matched or beat aflibercept during that loading phase, but gave no figures. Tabirafusp-ted, which combines IL-6 blocking with a VEGF trap, also met a key anatomical secondary goal, though the reports did not name the measure.

Markets: indices, currencies and commodities

Durability is the selling point

Zenkuda, or tarcocimab tedromer, is an anti-VEGF drug designed to stay in the eye longer. Its average half-life in the human eye is about 20 days, roughly three times that of approved anti-VEGF drugs.

That is why the 54% figure matters. Patients with wet AMD typically need repeated injections into the eye, and stretching the gap to six months would mean far fewer clinic visits. Patients only got another dose when scans showed fluid in the retina, a strict treat-to-dry rule. Chief executive Victor Perlroth said the data "positions us for the next stage of Kodiak's evolution".

There is no direct comparator for the six-month figure in this trial, and the results are company-reported and not yet peer-reviewed.

A comeback after earlier setbacks

The rally reflects how far expectations had fallen. Zenkuda failed an earlier wet AMD trial, DAZZLE, in 2022, when fixed dosing every 12 to 20 weeks did not match aflibercept. Two trials in diabetic macular oedema, GLEAM and GLIMMER, also failed in 2023, with cataracts reported in 19% of Zenkuda patients against 9% on aflibercept.

Since then the company has built a run of positive results. In DAYLIGHT, a 557-patient wet AMD trial, monthly Zenkuda matched aflibercept given every eight weeks. In GLOW2, 62.5% of Zenkuda patients with diabetic retinopathy improved by at least two steps on the severity scale, against 3.3% on sham treatment. It now counts five successful Phase 3 studies across three diseases: DAYBREAK and DAYLIGHT in wet AMD, GLOW1 and GLOW2 in diabetic retinopathy, and BEACON in retinal vein occlusion.

What comes next

  • A Biologics License Application for Zenkuda in the fourth quarter of 2026, covering wet AMD, diabetic retinopathy and retinal vein occlusion
  • The ALTO Phase 3 trial of tabirafusp-ted in diabetic macular oedema, planned at about 910 patients
  • First topline results from KSI-101 in inflammatory macular oedema, expected in December 2026

Kodiak has no approved product yet. Approval is not assured, and the company still has to show that the durability holds up in a second year of data.

Sources

Related stories

Markets

Novartis Suffers Its Worst Day on Record, Down 10.9%, After Two Late-Stage Trial Failures

Novartis fell 10.89% to CHF 111.80 on 8 September, its worst day on record, after del-desiran, the lead drug from its $12bn Avidity deal, missed its main goal, days after…

Markets

Bitcoin Posts Its Best Weekly Close Since January, Then Slips Under $83,000

Bitcoin closed last week near $84,450, its highest weekly close since late January, then fell below $82,700 on Monday as about $70 million of leveraged long bets were wiped out.

Markets

Uranium Energy Ends Fiscal 2026 Debt-Free With $495m Cash as Quarterly Output Jumps 157%

Uranium Energy Corp sold 400,000 pounds at an average $93.13 in the year to July, lifted fourth-quarter output 157% and ended the year with $495m of cash, no debt and lower costs…

Markets

Rocket Lab Signs Its Biggest Electron Deal: 20 Launches for Japan's Synspective

Rocket Lab will fly 20 radar satellites for Tokyo's Synspective from 2028 to 2031, its largest commercial Electron contract, lifting its launch backlog past 100 missions.

Markets

Bitcoin Falls to $62,000 as $2bn of Leveraged Bets Are Wiped Out in Sixth Weekly Loss

Bitcoin fell to about $62,000 at the weekend as $2bn of leveraged bets were liquidated, its sixth straight weekly loss. It was back near $65,000 on Monday, with $60,000 the next…

Markets

Copper Hits a Four-Month Low at $13,210 as AI Doubts Drag European Miners Down 2.3%

Copper fell to $13,210 a tonne on Monday, a four-month low about 10% below September's record, as AI doubts and weak Chinese data hit metals and Europe's basic resources shares…

Markets

Bessent Urges an Outside CEO for Nvidia as Shares Fall 4.1% Before Results

Treasury Secretary Scott Bessent wants Nvidia to hire an outside chief executive, the board is not discussing Jensen Huang's return, and the shares fell 4.1% on Monday, a day…

Markets

Chip Index Sinks 5.28% With All 30 Stocks Down, Dragging the Nasdaq 2.49% Before Nvidia

The Philadelphia Semiconductor Index fell 5.28% on Monday 16 November with all 30 members down, pulling the Nasdaq 2.49% lower and the Dow down 739 points before Nvidia reports.